Tumor mutational burden as a predictive biomarker in solid tumors
Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase
of interrogated genomic sequence, varies across malignancies. Panel sequencing–based …
of interrogated genomic sequence, varies across malignancies. Panel sequencing–based …
Neoantigens: promising targets for cancer therapy
Recent advances in neoantigen research have accelerated the development and regulatory
approval of tumor immunotherapies, including cancer vaccines, adoptive cell therapy and …
approval of tumor immunotherapies, including cancer vaccines, adoptive cell therapy and …
Tumor mutational burden as a predictor of immunotherapy response: is more always better?
Immune checkpoint inhibitors, including antibodies that block programmed cell death protein-
1 (PD-1) and PD-L1, have transformed the management of many cancers. However, the …
1 (PD-1) and PD-L1, have transformed the management of many cancers. However, the …
The status of tumor mutational burden and immunotherapy
Tumor mutational burden (TMB) has received significant attention within ongoing pursuits of
biomarkers of response to immune checkpoint inhibitors, and notably received FDA …
biomarkers of response to immune checkpoint inhibitors, and notably received FDA …
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C …
S Peters, R Dziadziuszko, A Morabito, E Felip… - Nature medicine, 2022 - nature.com
Tumor mutational burden (TMB) is being explored as a predictive biomarker for cancer
immunotherapy outcomes in non-small cell lung cancer. BFAST (NCT03178552)—an open …
immunotherapy outcomes in non-small cell lung cancer. BFAST (NCT03178552)—an open …
[HTML][HTML] Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project
DM Vega, LM Yee, LM McShane, PM Williams… - Annals of …, 2021 - Elsevier
Background Tumor mutational burden (TMB) measurements aid in identifying patients who
are likely to benefit from immunotherapy; however, there is empirical variability across panel …
are likely to benefit from immunotherapy; however, there is empirical variability across panel …
Tumour mutational burden as a biomarker for immunotherapy: current data and emerging concepts
JD Fumet, C Truntzer, M Yarchoan… - European Journal of …, 2020 - Elsevier
Abstract Treatment with immune checkpoint inhibitors targeting programmed cell death
protein 1 (PD-1) or its ligand (PD-L1) can generate durable responses in various cancer …
protein 1 (PD-1) or its ligand (PD-L1) can generate durable responses in various cancer …
Tumor mutational burden as a potential biomarker for immunotherapy in pancreatic cancer: systematic review and still-open questions
Simple Summary Tumor mutational burden (TMB) represents the number of mutations per
megabase (muts/Mb) harbored by tumor cells in a given neoplasm, and can be determined …
megabase (muts/Mb) harbored by tumor cells in a given neoplasm, and can be determined …
The predictive value of tumor mutation burden on efficacy of immune checkpoint inhibitors in cancers: a systematic review and meta-analysis
Y Wu, J Xu, C Du, Y Wu, D Xia, W Lv, J Hu - Frontiers in oncology, 2019 - frontiersin.org
Background: Despite an increasing understanding about tumor mutation burden (TMB) in
cancer immunity and cancer immunotherapy, the comprehensive cognition between TMB …
cancer immunity and cancer immunotherapy, the comprehensive cognition between TMB …
The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells
J Li, Z Xiao, D Wang, L Jia, S Nie, X Zeng, W Hu - Molecular Cancer, 2023 - Springer
Recent advances in neoantigen research have accelerated the development of tumor
immunotherapies, including adoptive cell therapies (ACTs), cancer vaccines and antibody …
immunotherapies, including adoptive cell therapies (ACTs), cancer vaccines and antibody …